top of page

GLP-1とSGLT2i併用が2型DMで心腎保護

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024 Apr 25;385:e078242. doi: 10.1136/bmj-2023-078242. PMID: 38663919; PMCID: PMC11043905.

24/4/25

BMJ

観察研究

英国プライマリケア疾患コホートPSマッチ

GLP-1 + SGLT2i vs GLP-1で 
心血管複合 0.70(0.49~0.99)、腎 0.43(0.23~0.80)

SGLT2i + GLP-1 + vs SGLT2iで 
心血管複合 0.71(0.52~0.98)
腎 0.67(0.32~1.41)

bottom of page